XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Apr. 15, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-33500    
Entity Registrant Name Jazz Pharmaceuticals plc    
Entity Incorporation, State or Country Code L2    
Entity Tax Identification Number 98-1032470    
Entity Address, Address Line One Fifth Floor, Waterloo Exchange    
Entity Address, Address Line Two Waterloo Road    
Entity Address, City or Town Dublin 4    
Entity Address, Country IE    
Entity Address, Postal Zip Code D04 E5W7    
Country Region 353    
City Area Code 1    
Local Phone Number 634-7800    
Title of 12(b) Security Ordinary shares, nominal value $0.0001 per share    
Trading Symbol JAZZ    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Smaller Reporting Company false    
Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 6,413,308,100
Entity Common Stock, Shares Outstanding   61,632,292  
Documents Incorporated by Reference
None
    
Amendment Flag true    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001232524    
Amendment Description The registrant is filing this Amendment to amend the 2024 Annual Report on Form 10-K as filed by the registrant with the SEC on February 26, 2025. The principal purpose of this Amendment is to include in Part III the information that was to be incorporated by reference from the proxy statement for the registrant’s 2025 Annual General Meeting of Shareholders, as well as to update certain of the information included on the cover page of the 2024 Annual Report on Form 10-K and in the list of exhibits included in Item 15 and the Exhibit Index of this report. This Amendment hereby amends the cover page, Part III, Items 10 through 14, and Part IV, Item 15 of the 2024 Annual Report on Form 10-K. In addition, as required by Rule 12b-15 under the Exchange Act, new certifications by the registrant’s principal executive officer and principal financial officer are filed as exhibits to this Amendment.No attempt has been made in this Amendment to modify or update the other disclosures presented in the 2024 Annual Report on Form 10-K. This Amendment does not reflect events occurring after the filing of the original report (i.e., those events occurring after February 26, 2025) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the 2024 Annual Report on Form 10-K and the registrant’s other filings with the SEC.In this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the registrant,” “the company,” “we,” “us,” “Jazz,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction in connection with which Azur Pharma was renamed Jazz Pharmaceuticals plc, and we became the parent company of and successor to Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. becoming our wholly owned subsidiary.